[PRNewswire] Hologic Inc (NASDAQ:HOLX)(TREND ANALYSIS) announced the Company’s financial results for the second fiscal quarter ended March 28, 2015. Quarterly revenues of $655.5 million increased 4.9% on a reported basis, and 7.2% on a constant currency basis. Non-GAAP earnings per share (EPS) increased 10.8%, to $0.41.
“We posted strong organic revenue growth across the board for a second straight quarter, while profitability increased at an even faster rate,” said Steve MacMillan, Hologic’s President and Chief Executive Officer. “As a Company, we have come a long way in a short period of time. While we focus on continuing to improve our performance, we are increasingly confident in our people and products, and are therefore further raising our financial outlook for the year.”
Stock Performance: Click here for a free comprehensive Trend Analysis Report
HOLX reported last quarter earnings on April 29. The X-Ray Equipment company announced earnings per share of $0.41 against a consensus Street estimate of $0.39, beating the average estimate by $0.02. This corresponds to an increase of $0.08 compared to the same quarter of the previous fiscal year.
Hologic Inc (NASDAQ:HOLX) is currently trading 0.62% below its 52-week-high, 51.74% above its 52-week-low. The 1-year range for the stock is $22.7 – $34.66. Hologic Inc (HOLX) has a price to earnings ratio of 84.63 versus Healthcare sector average of 39.05. HOLX stock price has outperformed the Nasdaq by 22.7%. The X-Ray Equipment company is currently valued at $9.68 billion and its share price closed the last trading session at $34.445. The stock has a 50-day moving average of $33.32 and a 200-day moving average of $29.89.
Hologic Inc (HOLX) current short interest stands at 8.32 million shares. It has increased by 7% from the same period of last month. Around 3% of the company’s shares, which are float, are short sold. With a 10-days average volume of 1.24 million shares, the number of days required to cover the short positions stand at 6.7 days.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently twenty-one analysts that cover HOLX stock. Of those twenty-one, twelve have a Buy rating, eight have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $36.03.
A recent analyst activity consisted of Jefferies reiterating their Buy stance on April 30. Jefferies increased their price target on HOLX from $34 to $38. This corresponds to a 10.32% upside from the last closing price. On the date of report, the stock closed at $33.74.
Barclays reiterated their Underweight stance on the same day, and increased their price target on HOLX stock from $26 to $31. This corresponds to a 10% downside from the last closing price. On the date of report, the stock closed at $33.74.
Another research firm was UBS who initiated their coverage on the stock with Buy rating on March 10. On the date of report, the stock closed at $31.92.
Hologic, Inc. develops, manufactures, and markets x-ray systems. The Company makes x-ray bone densitometers that measure the precise bone density for use in the diagnosing of metabolic bone diseases such as osteoporosis.